Donepezil for the treatment of agitation in Alzheimer's disease.

Author: , BallardClive G, BenthamPeter, BrownRichard G, BullockRoger, BurnsAlistair S, DeCesareJulia, HolmesClive, HowardRobert J, JacobyRobin, JohnsonTony, JonesRoy W, JuszczakEdmund, KatonaCornelius, KnappMartin, LindesayJames, O'BrienJohn T, RodgerMichaela, WilcockGordon

Paper Details 
Original Abstract of the Article :
BACKGROUND: Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. METHODS: We randomly assigned 272 patients with Alzheimer's...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1056/NEJMoa066583

データ提供:米国国立医学図書館(NLM)

Treating Agitation in Alzheimer's Disease: Donepezil's Role

This research delves into the challenging world of Alzheimer's disease, focusing on the common and distressing symptom of agitation. The researchers investigated the effectiveness of donepezil, a cholinesterase inhibitor commonly used to treat cognitive decline in Alzheimer's, in alleviating agitation. They conducted a randomized controlled trial to compare the effects of donepezil to placebo in patients with Alzheimer's disease who experienced significant agitation.

A Tale of Two Outcomes: Donepezil's Impact on Agitation

The researchers found that donepezil was not more effective than placebo in reducing agitation in patients with Alzheimer's disease. They observed no significant difference in agitation scores between the donepezil and placebo groups after 12 weeks of treatment. This highlights the need for further research to explore alternative approaches to managing agitation in Alzheimer's disease. It's like searching for a hidden oasis in the desert – while donepezil has proven effective for cognitive symptoms, it doesn't seem to offer the same relief for agitation.

A Continued Search: Seeking Effective Solutions

This research underscores the complexity of Alzheimer's disease and the need for ongoing research to develop more effective treatments for its various symptoms. It's like navigating a vast and shifting desert landscape – finding the right solutions for each patient's needs requires ongoing exploration and innovation.

Dr.Camel's Conclusion

Agitation in Alzheimer's disease is a challenging desert to navigate. While donepezil is a valuable tool for cognitive symptoms, it doesn't seem to offer much relief for agitation. It's a reminder that the search for effective treatments for this complex disease continues, seeking new oases of hope in the vast expanse of Alzheimer's.

Date :
  1. Date Completed 2007-10-09
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

17914039

DOI: Digital Object Identifier

10.1056/NEJMoa066583

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.